PET-Guided Navigation with Electromagnetic Tracking during PSMA-RadioGuided Surgery: Innovative Bimodal Detection of Nodal Metastases in Prostate Cancer Patients
Key facts
- Where
- Milan, OlaszországSee the site
- Phase
- 2. fázis
Where in Olaszország
- Ospedale San Raffaele S.r.l.Milan, OlaszországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ospedale San Raffaele S.r.l.
- Trial code
- EU 2026-526915-12-00
- Record updated
- 2026. október 19.
- Original description
To evaluate the role of PSMA-PET-guided navigation with electromagnetic tracking combined with PSMA-RGS to improve bCR rate (PSA <0.1 ng/mL at 6 weeks after surgery) in miN1 PCa patients with primary or recurrent disease undergoing RARP + ePLND or SLND.Read full original descriptionShow less
To evaluate the role of PSMA-PET-guided navigation with electromagnetic tracking combined with PSMA-RGS to improve bCR rate (PSA <0.1 ng/mL at 6 weeks after surgery) in miN1 PCa patients with primary or recurrent disease undergoing RARP + ePLND or SLND.
Inclusion: Male participants who are at least 18 years of age on the day of signing informed consent - Ability to provide written informed consent - Newly diagnosed miN1M0 Pca or oligorecurrent miN1M0 PCa - Eligibility for RARP and ePLND or SPLND.
Exclusion: Neoadjuvant or adjuvant, previous or concomitant hormonal treatment for prostate cancer - Inability to complete the imaging protocol - miM1 at PSMA-PET - Contraindications to the planned surgical procedure, including robot-assisted surgery - Cardiac pacemaker which can cause interference with the navigation system.